This meta-analysis suggests that patiromer and sodium zirconium cyclosilicate (SZC) represent significant pharmacologic advancements in the treatment of hyperkalemia. The former was filed for approval in EU in April 2016 for the treatment of hyperkalaemia and the marketing authorisation application for the latter received a positive opinion in EU in February 2017 for treatment of acute and chronic hyperkalaemia.